Back to top
more

Medpace (MEDP)

(Delayed Data from NSDQ)

$326.26 USD

326.26
747,101

+5.68 (1.77%)

Updated Sep 26, 2024 04:00 PM ET

After-Market: $326.58 +0.32 (0.10%) 7:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (156 out of 252)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Align (ALGN) Hurt by Dental Practice Closures, FX Headwind

by Zacks Equity Research

Align (ALGN) competes with products similar to Invisalign Technology, such as the products from Ormco Orthodontics, a division of Sybron Dental Specialties.

Here's Why Investors Should Retain Chemed (CHE) Stock Now

by Zacks Equity Research

Strong performance across Chemed's (CHE) Roto-Rooter arm and increased home-based admissions raise investors' confidence.

Here's Why Investors Should Retain SmileDirectClub (SDC) Now

by Zacks Equity Research

Investors are optimistic about SmileDirectClub's (SDC) better-than-expected revenues and new product launches.

LabCorp (LH) Rides on Innovations Amid Cost Constraints

by Zacks Equity Research

LabCorp's (LH) slew of product launches and collaborations to pursue short- and long-term high-growth opportunities instill optimism.

Here's Why You Should Retain Boston Scientific (BSX) for Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific's (BSX) strong organic sales and notable acquisitions.

Abbott (ABT) Medical Devices Arm Gains Traction, FX Woe Stays

by Zacks Equity Research

Within Abbott's (ABT) Nutrition arm, while the pediatric nutrition business witnesses a drag, the adult nutrition business continues to perform well.

Amedisys (AMED) Contessa's New JV Broadens At-Home Care Range

by Zacks Equity Research

Amedisys' (AMED) latest initiative aims at providing patients with a high-quality continuum of care in the home.

Thermo Fisher's (TMO) Autoimmune Disease Test Gets FDA Nod

by Zacks Equity Research

Thermo Fisher's (TMO) RNA Polymerase III and EliA Rib-P blood tests are intended to diagnose systemic sclerosis and systemic lupus erythematosus.

Here's Why Investors Should Retain Alcon (ALC) Stock For Now

by Zacks Equity Research

Investors are optimistic about Alcon's (ALC) better-than-expected results and robust performance across its popular franchises.

Thermo Fisher (TMO) to Promote Mass Spectrometry Imaging

by Zacks Equity Research

Thermo Fisher's (TMO) new deal with TransMIT will advance the use of the AP-SMALDI5 AF ion source with Orbitrap MS technology for spatial multi-omics applications.

PerkinElmer's (PKI) Latest Launch to Expand Food Safety Suite

by Zacks Equity Research

PerkinElmer's (PKI) microbial plates minimize human error by providing standardized protocols and offer a small footprint to save space in incubators and storage areas.

Henry Schein (HSIC) Inks New Deal to Acquire Condor Dental

by Zacks Equity Research

Henry Schein's (HSIC) acquisition of a Switzerland-based dental distribution company will strengthen its presence in the attractive European market.

Bruker (BRKR) to Advance 4D Proteomics With Latest Launch

by Zacks Equity Research

Bruker's (BRKR) timsTOF HT is enhanced for high-throughput, deep and unbiased plasma proteomics, and liquid biopsy biomarker research.

Here's Why Investors Should Retain Globus Medical (GMED) Now

by Zacks Equity Research

Globus Medical's (GMED) strong international growth and meaningful product launches raise investors' optimism.

Neogen (NEOG) to Offer New Biosecurity Solution in Canada

by Zacks Equity Research

Neogen's (NEOG) newest addition to the biosecurity portfolio is anticipated to curb the spread of diseases like COVID-19 and avian influenza.

Tandem Diabetes (TNDM) Posts Positive Control-IQ Study Data

by Zacks Equity Research

Data presented at the ADA conference demonstrates Tandem Diabetes' (TNDM) Control-IQ technology's ability to make a positive and sustained impact across a diverse group of people with diabetes.

Here's Why You Should Hold on to NuVasive (NUVA) Stock for Now

by Zacks Equity Research

Investors are optimistic about NuVasive (NUVA) on strong sales performance across the U.S. spinal hardware and the U.S. surgical support product lines.

Insulet (PODD) Reports Pivotal Extended Phase Data for Omnipod 5

by Zacks Equity Research

Insulet's (PODD) Omnipod 5 showed improved time in range and lower HbA1c for pre-school children during an extended phase of the previous pivotal trial.

Bio-Rad (BIO) Immunohematology Arm Recovers, New Launches Aid

by Zacks Equity Research

Bio-Rad's (BIO) qPCR business is experiencing excellent uptake from the new-generation CFX Opus platform.

Boston Scientific (BSX) Gains from New Buyouts, FX Issue Ails

by Zacks Equity Research

Boston Scientific (BSX) is currently looking forward to launching its arterial and venous offerings in the second half of 2022.

Abbott (ABT) FreeStyle Libre 3 System's Study Outcome Favorable

by Zacks Equity Research

Abbott's (ABT) FreeStyle Libre 3 system is the first and only 14-day CGM system with an overall MARD of 7.9%.

Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics (DGX) on a strong recovery in the base business and the raised 2022 outlook.

Here's Why You Should Retain Bruker (BRKR) Stock for Now

by Zacks Equity Research

Investors are optimistic about Bruker (BRKR) on strength across the BSI and BEST businesses.

Phibro (PAHC) Business Hurt by Macro Issues, FX Fluctuations

by Zacks Equity Research

The increase in raw material costs and freight costs continues to pose challenges for Phibro (PAHC).

Here's Why Investors Should Retain Omnicell (OMCL) Stock Now

by Zacks Equity Research

Investors are optimistic about Omnicell's (OMCL) better-than-expected results and new launches.